We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $931M
1-Year Est. Return 41.63%
This Fund
S&P 500
This Quarter Est. Return
+51.2%
1 Year Est. Return
+41.63%
3 Year Est. Return
+181.18%
5 Year Est. Return
+113.34%
10 Year Est. Return
+1,823.73%
AUM
$3.01B
AUM Growth
+$676M
Cap. Flow
-$168M
Cap. Flow %
-5.59%
Top 10 Hldgs %
75.26%
Holding
119
New
16
Increased
18
Reduced
26
Closed
23

Top Buys

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$54.2M
2
SRRK icon
Scholar Rock
SRRK
+$27.3M
3
ARWR icon
Arrowhead Research
ARWR
+$27.2M
4
PRTA icon
Prothena Corp
PRTA
+$19.3M
5
KRRO icon
Korro Bio
KRRO
+$13.8M

Top Sells

Rank Stock Value
1
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$114M
2
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
+$46.9M
3
IMGN
Immunogen Inc
IMGN
+$24M
4
FOLD
Amicus Therapeutics
FOLD
+$23.1M
5
RVMD icon
Revolution Medicines
RVMD
+$20M

Sector Composition

Rank Sector Weight
1 Healthcare 50.36%
2 Consumer Discretionary 46.45%
3 Miscellaneous 2.48%
4 Technology 0.44%
5 Real Estate 0.13%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
INTA icon
76
Intapp
INTA
$2.87B
$665K 0.02%
17,500
+7,500
+75% +$276K
PCOR icon
77
Procore
PCOR
$7.99B
$658K 0.02%
9,500
+5,000
+111% +$308K
V icon
78
Visa
V
$701B
$651K 0.02%
2,500
-5,000
-67% -$1.23M
CRBU icon
79
Caribou Biosciences
CRBU
$136M
$604K 0.02%
105,347
– –
ME
80
DELISTED
23andMe Holding Co
ME
$604K 0.02%
33,050
– –
LLY icon
81
Eli Lilly
LLY
$1.01T
$583K 0.02%
+1,000
New +$584K
PEGA icon
82
Pegasystems
PEGA
$6.19B
$562K 0.02%
23,000
+8,000
+53% +$187K
RELY icon
83
Remitly
RELY
$4.62B
$486K 0.02%
+25,000
New +$560K
CYCN
84
DELISTED
Cyclerion Therapeutics
CYCN
$466K 0.02%
138,955
– –
CFLT
85
DELISTED
Confluent
CFLT
$445K 0.01%
+19,000
New +$459K
MDB icon
86
MongoDB
MDB
$30.4B
$409K 0.01%
+1,000
New +$379K
CWAN
87
DELISTED
Clearwater Analytics
CWAN
$401K 0.01%
+20,000
New +$394K
AMD icon
88
Advanced Micro Devices
AMD
$823B
$369K 0.01%
2,500
-3,500
-58% -$413K
DLO icon
89
dLocal
DLO
$4.25B
$354K 0.01%
+20,000
New +$358K
PYPL icon
90
PayPal
PYPL
$46B
$307K 0.01%
5,000
– –
XLO icon
91
Xilio Therapeutics
XLO
$59.4M
$248K 0.01%
32,143
– –
HIPO icon
92
Hippo Holdings
HIPO
$859M
$219K 0.01%
24,000
– –
CERE
93
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
$214K 0.01%
5,041
-1,633,817
-100% -$46.9M
GOSS icon
94
CALL
Gossamer Bio
GOSS
$63.4M
$189K 0.01%
+2,588
New +$153K
SNTI icon
95
Senti Biosciences Holdings
SNTI
$9.34M
$37K ﹤0.01%
5,556
– –
INKT icon
96
MiNK Therapeutics
INKT
$58.2M
$2K ﹤0.01%
192
– –
ADAP
97
DELISTED
Adaptimmune Therapeutics
ADAP
– –
-1,133,775
Closed -$884K
ALNY icon
98
Alnylam Pharmaceuticals
ALNY
$31.9B
– –
-936
Closed -$166K
AUPH icon
99
Aurinia Pharmaceuticals
AUPH
$2.15B
– –
-1,000,000
Closed -$7.77M
BEAM icon
100
Beam Therapeutics
BEAM
$2.4B
– –
-10,975
Closed -$264K
1 2 3
4
5

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $931M AUM 47.97% 1-Year Est. Return
ACM
Ashe Capital Management Englewood Cliffs, New Jersey $931M AUM 4.95% 1-Year Est. Return
SAM
Sycomore Asset Management Paris, France $932M AUM 51.25% 1-Year Est. Return
NS
Night Squared New York $930M AUM 56.46% 1-Year Est. Return
PA
Planning Alternatives Birmingham, Michigan $933M AUM 28.32% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $933M AUM 56.2% 1-Year Est. Return
CICI
Capital Investment Counsel Inc Raleigh, North Carolina $929M AUM 53.07% 1-Year Est. Return
CAM
Claret Asset Management Montreal, Quebec, Canada $928M AUM 25.4% 1-Year Est. Return

Artal Group's Q4 2023 Portfolio in Review

As of Q4 2023, Artal Group held 119 positions worth $3.01B, up 29% from $2.33B the previous quarter. Its ten largest holdings account for 75% of the portfolio.

Artal Group withdrew a net $168M in Q4 2023, closing 23 positions and reducing 26 holdings. Its most notable exit was Mirati Therapeutics, Inc. Common Stock, an estimated $114M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 50% of assets, down from 54% a quarter earlier, followed by Consumer Discretionary and Miscellaneous.

Against the trend, Artal Group opened a new position in argenx worth $44.3M.

  • Artal Group's largest Q4 2023 buy was argenx: 116,388 shares worth $44.3M.
  • Artal Group added most to Scholar Rock in Q4 2023, an estimated $27.3M increase.
  • Artal Group's biggest Q4 2023 reduction was Cerevel Therapeutics Holdings, Inc. Common Stock, cutting an estimated $46.9M.
  • Artal Group fully exited Mirati Therapeutics, Inc. Common Stock in Q4 2023, selling an estimated $114M.
  • Artal Group's ten largest holdings make up 75% of its $3.01B portfolio in Q4 2023.
  • Artal Group opened 16 new positions and closed 23 in Q4 2023.
  • Artal Group's portfolio value rose 29% quarter-over-quarter to $3.01B.

Based on Artal Group's 13F filing for Q4 2023, filed 9 Feb 2024.